1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Starpharma Holdings Limited

Starpharma Holdings Limited

SPHRF
Starpharma Holdings LimitedUS flagOther OTC
0.52
USD
- -
- -
224.68MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
- -
- -
- -
0.01
0.01
0.01
- -
0.02
- -
0.01
0.01
0.02
0.01
Basic EPS, GAAP
-0.02
-0.05
-0.06
-0.07
0.02
-0.03
-0.04
-0.04
-0.05
-0.04
-0.04
-0.02
-0.02
Free Cash Flow per Basic Share
-0.04
-0.04
-0.05
-0.05
-0.05
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.15
0.1
0.1
0.11
0.14
0.11
0.07
0.03
0.1
0.05
0.02
- -
-0.03
Tangible Book Value per Share
0.13
0.09
0.09
0.12
0.17
0.14
0.11
0.08
0.16
0.12
0.09
0.07
0.05
Basic Weighted Avg Shares
283
284
310
345
368
370
371
372
397
407
409
411
417
Sales/Revenue/Turnover
- -
- -
1
4
3
4
2
6
2
5
3
8
5
Operating Margin (%)
-43,420
-6,118.68
-2,619.28
-638.22
-560.13
-308
-946.15
-276.33
-1,243.33
-378.3
-620.48
-129.65
-244.26
Depreciation Expense
1
1
1
1
1
- -
- -
1
1
1
1
1
1
Net Income, GAAP
-5
-15
-19
-23
8
-10
-14
-15
-20
-16
-16
-8
-10
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-26,145
-5,360.81
-2,356.97
-592.81
274.06
-269.81
-863.36
-243.3
-1,097.44
-345.02
-532.09
-98.5
-203.38
Working Capital
37
25
28
41
60
52
41
30
60
50
33
26
17
LT Debt
- -
- -
- -
- -
- -
- -
- -
1
- -
7
3
2
1
Total Equity
46
33
38
49
61
53
42
31
62
48
35
28
19
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-11.72
-41.48
-65.59
-65.42
18.28
-22.87
-43.55
-80.19
-80.2
-53.55
-109.26
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.74%
-0.63%
-32.43%
Free Cash Flow
2.58%
34.55%
-52.81%
Net Income, GAAP
-31.27%
-2.47%
22.35%
Sales/Revenue/Turnover
78.44%
38.85%
-40.74%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
3
2024
- -
- -
- -
- -
8
2025
- -
- -
- -
- -
5

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.04
2024
- -
- -
- -
- -
-0.02
2025
- -
- -
- -
- -
-0.02

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Cheryl Maley
Full Time Employees
40
Sector
Healthcare
Industry
Biotechnology
Address
4-6 Southampton Crescent Abbotsford VIC Australia 3067
IPO Date
Apr 30, 2007
Website
starpharma.com
Similar Companies
Gossamer Bio, Inc. (GOSS)
Baseline Productions, Inc. (BSSP)
Palisade Bio, Inc. (PALI)
Vincerx Pharma, Inc. (VINCU)
NetScientific plc (NSCI.L)
Fennec Pharmaceuticals Inc. (FRX.TO)
Business
Starpharma Holdings Limited (ASX:SPL, OTC:SPHRY) is an Australia-based biotechnology company that researches, develops, and commercializes dendrimer products for pharmaceutical, life-science, and healthcare applications; its core offerings include the DEP (dendrimer enhanced product) drug delivery platform featuring clinical-stage oncology assets such as DEP SN38, DEP cabazitaxel, and DEP docetaxel for improved chemotherapeutic delivery, preclinical radiopharmaceuticals and DEP antibody-drug conjugates (ADCs) targeting solid tumors including DEP HER2 radiodiagnostic and DEP HER2 ADC, over-the-counter products VivaGel BV (a non-antibiotic vaginal gel for bacterial vaginosis treatment and prevention), VivaGel Condom, and VIRALEZE antiviral nasal spray for trapping respiratory viruses; the company operates primarily in oncology, women's health, and antivirals, with commercial products available in approximately 35 countries and a pipeline advanced through over 350 patients treated in clinical programs. Founded in 1996 as a spin-off from CSIRO and headquartered in Abbotsford, Victoria, Australia, Starpharma maintains subsidiaries including Starpharma Pty Ltd in Melbourne and focuses on global partnerships with pharmaceutical leaders, academic institutions, and contract development organizations for drug enhancement across small molecules, antibodies, and radiotheranostics. Recent developments include an exclusive oncology licensing agreement with Genentech valued at up to A$860 million plus royalties in 2025, a research collaboration with Radiopharm Theranostics offering exclusivity options also in 2025, ongoing joint venture with Medicxi via Petalion Therapeutics for novel cancer therapies, plans for first-in-patient clinical trials of radiopharmaceutical assets in 2026, progression of three Phase 2 assets for licensing, and strengthened commercial sales of VivaGel and VIRALEZE following the 2024 conclusion of the AstraZeneca partnership to reallocate resources.